Literature DB >> 30562602

Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.

Manisha Jain1, Amit Sharma1, M K Sen2, Vandana Rani1, Rajni Gaind3, J C Suri2.   

Abstract

BACKGROUND: Multi-drug resistant Acinetobacter baumannii has emerged as important nosocomial pathogen associated with various infections including lower respiratory tract. Limited therapeutic options contribute to increased morbidity and mortality. Acinetobacter baumannii has the ability to persist in the environment for prolonged periods. Breach in infection control practices increases the chances of cross transmission between patients and inter/intraspecies transmission of resistance elements. The present prospective work was conducted among patients with lower respiratory tract infections (LRTI) in the intensive care unit (ICU) to study the etiology with special reference to Acinetobacter baumannii and the role of immediate patient environment in the ICU as possible source of infection. Acinetobacter baumannii were characterized for antimicrobial susceptibility, mechanism of carbapenem resistance and virulence determinants. Molecular typing of the clinical and environmental isolates was undertaken to study the probable modes of transmission.
MATERIALS AND METHODS: Appropriate respiratory samples from 107 patients with LRTI admitted to ICU during September 2016 to March 2017 were studied for likely bacterial pathogens. Environmental samples (n = 71) were also screened. All the samples were processed using conventional microbiological methods. Consecutive Acinetobacter spp. isolated from clinical and environmental (health care workers and environment from ICU) samples were included in the study. Antimicrobial susceptibility was performed as per CLSI guidelines. Carbapenem resistance, mediated by carbapenemase genes (blaOXA-23-like,blaOXA-24-like,blaOXA-58-like and blaNDM-1) were studied by PCR. Biofilm forming ability was tested phenotypically using microtitre plate method. Pulse Field Gel Electrophoresis (PFGE) was used to study clonality of the clinical and environmental isolates.
RESULTS: The prevalence of Acinetobacter baumannii was 26.2% (28/107) and 11.26% (8/71) among patients with LRTI and environmental samples respectively. The carbapenem resistance was high, 96.42% (27/28) and 87.5% (7/8) in clinical and environmental isolates respectively. The most common carbapenemase associated with resistance was blaOXA-23-like gene followed by blaNDM-1 among both the clinical and environmental isolates. All isolates were sensitive to colistin (MIC ≤ 1 μg/ml). Biofilm production was observed among all clinical (n = 28) and 87.5% (7/8) of the environmental isolates. Line listing of the cases suggests the occurrence of infections throughout the study period with no significant clustering. On PFGE, 12 clusters were observed and 16/36 isolates were present in one single cluster that included both clinical and environmental isolates which were either carbapenem resistant or sensitive. DISCUSSION: Carbapenem resistant Acinetobacter baumannii (CRAB) is an important cause of LRTI in the ICU. PFGE suggests spread of carbapenem resistant isolates via cross transmission among patients and the environment. The detection of blaNDM-1 gene among Acinetobacter baumannii and existence of carbapenem resistant and sensitive isolates within the same clones suggests horizontal transmission of resistant genes among various bacterial species. The ability of Acinetobacter baumannii to form biofilms may contribute to its persistence in the environment. This along with breach in infection control practices are the likely factors contributing to this transmission. This information can be used to strengthen and monitor infection control (IC) and the hospital cleaning and disinfection practices to prevent spread of resistant organisms within the ICU. Colistin remains drug of choice for management of CRAB.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Carbapenem resistant Acinetobacter baumannii (CRAB); Lower respiratory tract infections (LRTI); Multidrug resistant; Pulse field gel electrophoresis (PFGE)

Mesh:

Substances:

Year:  2018        PMID: 30562602     DOI: 10.1016/j.micpath.2018.12.023

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  7 in total

1.  Case Commentary: Uncertainty in Evaluating Treatment Outcomes in Carbapenem-Resistant Acinetobacter baumannii Infections.

Authors:  Jessica Howard-Anderson; David van Duin
Journal:  Antimicrob Agents Chemother       Date:  2021-08-23       Impact factor: 5.191

2.  Distribution of carbapenemase genes in clinical isolates of Acinetobacter baumannii & a comparison of MALDI-TOF mass spectrometry-based detection of carbapenemase production with other phenotypic methods.

Authors:  Megha Sharma; Lipika Singhal; Vikas Gautam; Pallab Ray
Journal:  Indian J Med Res       Date:  2020-06       Impact factor: 2.375

3.  Antigen Epitope Developed Based on Acinetobacter baumannii MacB Protein Can Provide Partial Immune Protection in Mice.

Authors:  Xiaojie Song; Guanghui Zhao; Meiling Ding
Journal:  Biomed Res Int       Date:  2020-10-20       Impact factor: 3.411

4.  Investigation of Acinetobacter baumannii Activity in Vascular Surgery Units through Epidemiological Management Based on the Analysis of Antimicrobial Resistance, Biofilm Formation and Genotyping.

Authors:  Anna Szczypta; Katarzyna Talaga-Ćwiertnia; Małgorzata Kielar; Paweł Krzyściak; Anna Gajewska; Mirosław Szura; Małgorzata Bulanda; Agnieszka Chmielarczyk
Journal:  Int J Environ Res Public Health       Date:  2021-02-07       Impact factor: 3.390

5.  Impact of an Intervention to Control Imipenem-Resistant Acinetobacter baumannii and Its Resistance Mechanisms: An 8-Year Survey.

Authors:  Lida Chen; Pinghai Tan; Jianming Zeng; Xuegao Yu; Yimei Cai; Kang Liao; Penghao Guo; Yili Chen; Zongwen Wu; Pinghua Qu; Renxin Cai; Cha Chen; Bin Huang
Journal:  Front Microbiol       Date:  2021-02-16       Impact factor: 5.640

6.  Pathogenic Characteristics and Risk Factors for ESKAPE Pathogens Infection in Burn Patients.

Authors:  Zhaoyinqian Li; Jingling Xie; Jiaxin Yang; Siyi Liu; Zixuan Ding; Jingchen Hao; Yinhuan Ding; Zhangrui Zeng; Jinbo Liu
Journal:  Infect Drug Resist       Date:  2021-11-12       Impact factor: 4.003

7.  Development of Loop-Mediated Isothermal Amplification Assay for Detection of Clinically Significant Members of Acinetobacter calcoaceticus-baumannii Complex and Associated Carbapenem Resistance.

Authors:  Amit Sharma; Rajni Gaind
Journal:  Front Mol Biosci       Date:  2021-06-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.